The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 2 rounds in the feed.
As life science venture investors, industry connectors, and company founders, Longwood Fund identifies and supports novel technologies and the teams behind them – advancing today’s most promising science into tomorrow’s treatments for patients who need them most.
Venture capitalBoston, MA, USAlongwoodfund.comRounds from 2026-04-13 to 2026-04-28
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Coultreon Biopharma Develop autoimmune disease treatments | Series A Verified against 1 of 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $125M | 2026-04-28 | [ PART ] |
Neomorph Neomorph develops molecular glue degraders to target and destroy disease-causing proteins. |
Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. |
| $100M |
| 2026-04-13 |
| [ PART ] |